These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16707411)

  • 1. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects.
    Marier JF; Lor M; Potvin D; Dimarco M; Morelli G; Saedder EA
    J Clin Pharmacol; 2006 Jun; 46(6):642-53. PubMed ID: 16707411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal fentanyl matrix patches Matrifen and Durogesic DTrans are bioequivalent.
    Kress HG; Boss H; Delvin T; Lahu G; Lophaven S; Marx M; Skorjanec S; Wagner T
    Eur J Pharm Biopharm; 2010 Jun; 75(2):225-31. PubMed ID: 20152899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation.
    Marier JF; Lor M; Morin J; Roux L; Di Marco M; Morelli G; Saedder EA
    Br J Clin Pharmacol; 2007 Jan; 63(1):121-4. PubMed ID: 16939522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers.
    Schmid-Grendelmeier P; Pokorny R; Gasser UE; Richarz U
    Curr Med Res Opin; 2006 Mar; 22(3):501-9. PubMed ID: 16574034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications.
    Sathyan G; Guo C; Sivakumar K; Gidwani S; Gupta S
    Curr Med Res Opin; 2005 Dec; 21(12):1961-8. PubMed ID: 16368047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.
    Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
    Clin Ther; 2006 May; 28(5):707-14. PubMed ID: 16861092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers.
    Vasisht N; Gever LN; Tagarro I; Finn AL
    J Clin Pharmacol; 2010 Jul; 50(7):785-91. PubMed ID: 20150521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers.
    Zecca E; Manzoni A; Centurioni F; Farina A; Bonizzoni E; Seiler D; Perrone T; Caraceni A
    Br J Clin Pharmacol; 2015 Jul; 80(1):110-5. PubMed ID: 25612845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study.
    Nave R; Connolly SM; Popper L; Lahu G; Schmitt H
    Int J Clin Pharmacol Ther; 2012 Oct; 50(10):751-9. PubMed ID: 22943926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats.
    Carroll GL; Hooper RN; Boothe DM; Hartsfield SM; Randoll LA
    Am J Vet Res; 1999 Aug; 60(8):986-91. PubMed ID: 10451210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of a new fentanyl tape with a novel delivery system of transdermal matrix patches in patients with cancer pain.
    Saito T; Fujii M; Saito S; Shimada K; Fujiwara K; Kobayashi K
    Oncology; 2014; 86(1):10-5. PubMed ID: 24335580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain.
    Freynhagen R; von Giesen HJ; Busche P; Sabatowski R; Konrad C; Grond S
    J Pain Symptom Manage; 2005 Sep; 30(3):289-97. PubMed ID: 16183013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
    Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
    Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal delivery of fentanyl from matrix and reservoir systems: effect of heat and compromised skin.
    Prodduturi S; Sadrieh N; Wokovich AM; Doub WH; Westenberger BJ; Buhse L
    J Pharm Sci; 2010 May; 99(5):2357-66. PubMed ID: 19967778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
    Lennernäs B; Hedner T; Holmberg M; Bredenberg S; Nyström C; Lennernäs H
    Br J Clin Pharmacol; 2005 Feb; 59(2):249-53. PubMed ID: 15676050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.